Prosecution Insights
Last updated: October 04, 2026

Neurovision Medical Products Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

The company patent portfolio for Neurovision Medical Products Inc. is focused on Biotechnology & Pharmaceuticals. Currently, the portfolio includes 1 pending office action. This 1 pending office action is being handled within 1 distinct art unit, reflecting a narrow technical scope for the company's current filings. Such a structure often points to a highly targeted intellectual property strategy.

A specific official, 1 distinct examiner, is responsible for the current workload. OGUNTADE, ELIZABETH BISOLA is the busiest examiner identified in the data, managing 1 busiest examiner pending office action. This concentration of the busiest examiner pending office action under 1 distinct examiner means that the prosecution strategy must be tailored to the specific individual's tendencies. The data shows that 1 distinct art unit is the venue for the company's current patent office interactions. Practitioners should prepare for an examination process that is entirely dependent on the findings of the assigned art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
OGUNTADE, ELIZABETH BISOLA 1 0.0% +0.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18083870 RAPID PARATHORMONE IDENTIFICATION TEST KIT OGUNTADE, ELIZABETH BISOLA —

Top Art Units

Art UnitApps
1677 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18083870 RAPID PARATHORMONE IDENTIFICATION TEST KIT OGUNTADE, ELIZABETH BISOLA 1677 §102§103§112 Non-Final OA — Pending Dec 19, 2022

Managing Neurovision Medical Products Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month